The long-term objective is to understand the genetic origins and biological functions of unique, (i.e. individually distinct) antigens. These antigens lead to rejection of regressor tumors when transplanted into naive mice and of progressor tumors when transplanted into pre- immunized mice. Two types of unique antigens recognized by CD8+ T cells will be analyzed: those that must be lost by regressors before they can grow in a naive mice and those that can be retained by progressor variants. In the first Aim, it will be determined whether expression of a somatically mutated p68 peptide indeed gives rise to the rejection of the regressor tumor, by analyzing whether re-expression of the mutant gene by an antigen-loss variant reverts from a progressor to a regressor phenotype. If this is observed, it will further be determined whether re- expression of this antigen is sufficient even in established cancer to elicit tumor rejection.
In Aim 2, it will be studies which changes in p68 helicase are observed in various cancers (in particular mutations and up- regulation of expression), and whether the already observed point mutation in the IQ domain of the gene results in oncogenic properties, while the wild-type p68 acts as a tumor suppressor gene. The main goal of Aim 3 is to confirm or refute the general principal that unique rejection antigens of UV-induced tumors are due to somatic mutations in a protein expressed at high levels in the cancer cells. The CD8+ T cell-defined unique 5117-RE tumor antigen which is consistently lost by progressor variants will be used as the model. If a mutant gene is identified, the potential significance of the mutations for the malignant process will be studied.
The fourth Aim will be to identify the genetic origins of unique antigens that are retained on primary and variant progressor tumors and are insufficient to elicit tumor rejection by naive mice. It will be examined whether these antigens are also encoded by somatic tumor-specific mutations and whether these mutant peptides are equally or less immunogenic than mutant peptides expressed only by regressor tumors. Finally, we will determine whether loss of heterozygosity of the mutant genes encoding unique antigens on the progressor tumors is responsible for the extreme resistance of certain CTL epitopes to immunoselection, and we will analyze in standard assays the relevance of the mutant genes to the development of malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA074182-03
Application #
6318308
Study Section
Project Start
2000-06-05
Project End
2001-04-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
3
Fiscal Year
2000
Total Cost
$151,166
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Binder, David C; Schreiber, Hans (2014) Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter. Cancer Res 74:632; discussion 635
Arina, Ainhoa; Schreiber, Karin; Binder, David C et al. (2014) Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J Immunol 192:1286-93
Schreiber, Karin; Arina, Ainhoa; Engels, Boris et al. (2012) Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 18:2526-33
Wu, Terry H; Schreiber, Karin; Arina, Ainhoa et al. (2011) Progression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genes. Cancer Immun 11:2
Gidalevitz, Tali; Biswas, Chhanda; Ding, Hua et al. (2004) Identification of the N-terminal peptide binding site of glucose-regulated protein 94. J Biol Chem 279:16543-52
Eiben, Gretchen L; Velders, Markwin P; Kast, W Martin (2002) The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. Adv Cancer Res 86:113-48
Salit, Rachel B; Kast, W Martin; Velders, Markwin P (2002) Ins and outs of clinical trials with peptide-based vaccines. Front Biosci 7:e204-13
Wakabayashi, Mark T; Da Silva, Diane M; Potkul, Ronald K et al. (2002) Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 45:300-7
Schreiber, H; Wu, T H; Nachman, J et al. (2002) Immunodominance and tumor escape. Semin Cancer Biol 12:25-31
Vogen, Shawn; Gidalevitz, Tali; Biswas, Chhanda et al. (2002) Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J Biol Chem 277:40742-50

Showing the most recent 10 out of 35 publications